Institutional investor Caligan Partners discloses a 10.3% stake of ~3.5M common shares in AMAG Pharmaceuticals (AMAG +5.7%). It has also filed a preliminary consent statement seeking the replacement of four board members with four candidates that it says will drive changes at the drug maker.
Investors appear to like the move albeit on below-average volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.